UCB (NASDAQ:UCBJF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Thursday. The firm presently has a $79.00 target price on the stock. Zacks Investment Research’s price objective points to a potential upside of 2.69% from the company’s current price.
According to Zacks, “UCB SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in providing therapy for central nervous system disorders, including epilepsy, diabetic neuropathic pain, sclerosis and Parkinson’s disease. It also provides therapy in the areas of oncology, immunology, inflammation, allergy and respiratory diseases. UCB delivers small and large molecule solutions to specialists for use in the treatment of severe diseases. “
UCB (NASDAQ:UCBJF) opened at 76.93 on Thursday. The stock has a market capitalization of $14.51 billion and a PE ratio of 25.96. The firm’s 50-day moving average is $72.24 and its 200 day moving average is $71.68. UCB has a 52-week low of $58.42 and a 52-week high of $83.23.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.